Related Experiment Videos
Insights
Valproic acid exposure during pregnancy can lead to severe birth defects. This case highlights multiple congenital malformations and developmental issues in an infant exposed to valproic acid in utero.
Area of Science:
- Teratology
- Developmental Biology
- Pediatric Medicine
Background:
- Valproic acid is an anticonvulsant and mood-stabilizing drug.
- Prenatal exposure to certain medications can cause congenital malformations.
- Understanding drug teratogenicity is crucial for prenatal care.
Observation:
- A neonate presented with multiple congenital anomalies following in utero exposure to valproic acid.
- Observed malformations included duodenal atresia, vertebral fusion, scoliosis, renal abnormalities, and diastasis recti abdominis.
- Additional findings included eyebrow depigmentation, a large hemangioma, neonatal hyperbilirubinemia, and postnatal growth deficiency.
Findings:
- The infant exhibited a complex pattern of congenital malformations consistent with valproic acid embryopathy.
- Neonatal complications and growth deficits were noted postnatally.
- This case adds to the evidence linking valproic acid to teratogenic effects in humans.
Implications:
- Reinforces the teratogenic potential of valproic acid during pregnancy.
- Underscores the importance of careful medication management in pregnant individuals.
- Highlights the need for comprehensive evaluation and management of infants exposed prenatally to valproic acid.
Abstract:
An infant exposed in utero to valproic acid was born with multiple congenital malformations, including duodenal atresia, lumbar vertebral fusion, thoracolumbar scoliosis, renal abnormalities, diastasis recti abdominis, depigmentation of the eyebrows, and a large hemangioma. The child had neonatal hyperbilirubinemia and postnatal growth deficiency. This case report is an addition to the literature implicating valproic acid as a human teratogen.